FLOW CYTOMETRIC ANALYSIS OF PRIMARY AND METASTATIC BLADDER-CANCER

被引:22
|
作者
BADALAMENT, RA
OTOOLE, RV
KEYHANIROFAGHA, S
BARKLEY, C
KENWORTHY, P
ACCETTA, P
WISE, H
PEREZ, JF
DRAGO, JR
机构
[1] RIVERSIDE METHODIST HOSP, DEPT PATHOL, COLUMBUS, OH 43214 USA
[2] DOCTORS HOSP, DEPT SURG, DIV UROL, COLUMBUS, OH USA
来源
JOURNAL OF UROLOGY | 1990年 / 143卷 / 05期
关键词
D O I
10.1016/S0022-5347(17)40134-0
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
A total of 22 patients with high grade P2-4N+ transitional cell carcinoma of the bladder underwent flow cytometric analysis of nuclei obtained from paraffin embedded specimens from the primary (bladder) and metastatic (lymph node) sites. Tumor heterogeneity was defined as polyclonal aneuploidy of the primary tumor (not identified in the population studied) or as a difference in the deoxyribonucleic acid index of the primary and metastatic sites of 0.20 or more (8 patients). With these criteria 8 patients (36%) had heterogeneous tumors and 14 (64%) had homogeneous tumors. The median survival of 14 patients with aneuploid and 8 with diploid primary tumors was 17.5 and 8.0 months, respectively (p equals 0.08, Lee-Desu test). When patient survival was compared to the ploidy of the metastatic site, or in patients with diploid primary and metastatic lesions versus deoxyribonucleic acid aneuploidy at either the primary and/or metastatic site, the aneuploid tumors had a longer survival but this difference was not significant (p equals 0.13 and 0.23, respectively). Our study demonstrates the value of flow cytometry to identify primary metastatic tumor heterogeneity. It also suggests that the presence of metastasis may be a more important factor to define the biological potential of transitional cell carcinoma than is deoxyribonucleic acid ploidy.
引用
收藏
页码:912 / 916
页数:5
相关论文
共 50 条
  • [21] MULTIVARIATE-ANALYSIS OF FLOW CYTOMETRIC DEOXYRIBONUCLEIC-ACID PARAMETERS AND HISTOLOGICAL FEATURES FOR PROGNOSIS OF BLADDER-CANCER PATIENTS
    TACHIBANA, M
    DEGUCHI, N
    BABA, S
    JITSUKAWA, S
    HATA, M
    TAZAKI, H
    JOURNAL OF UROLOGY, 1991, 146 (06): : 1530 - 1534
  • [22] CHEMOTHERAPY OF METASTATIC BLADDER-CANCER - RPMI EXPERIENCE
    HUBEN, RP
    DRAGONE, N
    TOMASELLO, E
    JOURNAL OF UROLOGY, 1986, 135 (04): : A278 - A278
  • [23] CHEMOTHERAPY FOR METASTATIC BLADDER-CANCER - IS THERE NEW HOPE
    WAXMAN, J
    BRITISH JOURNAL OF UROLOGY, 1990, 65 (01): : 1 - 5
  • [24] CHEMOTHERAPY IN THE MANAGEMENT OF INVASIVE AND METASTATIC BLADDER-CANCER
    RAGHAVAN, D
    EUROPEAN UROLOGY, 1988, 14 : 21 - 23
  • [25] COMBINED CHEMOTHERAPY IN THE MANAGEMENT OF METASTATIC BLADDER-CANCER
    GARCIAGIRALT, E
    AUVERT, J
    LACHAND, AT
    BOTTO, H
    ABBOU, C
    HANNOUN, M
    POUILLART, P
    PALANGIE, T
    JOUVE, M
    MORIN, P
    BRITISH JOURNAL OF UROLOGY, 1981, 53 (04): : 318 - 319
  • [26] PROGNOSIS IN BLADDER-CANCER - A STUDY OF CYTOMETRIC, MORPHOMETRIC AND IMMUNOHISTOCHEMICAL TECHNIQUES
    VASKO, J
    SCANDINAVIAN JOURNAL OF UROLOGY AND NEPHROLOGY, 1994, : 1 - &
  • [27] FLOW CYTOMETRIC ANALYSIS OF DNA STEMLINE HETEROGENEITY IN PRIMARY AND METASTATIC BREAST-CANCER - REPLY
    KUTE, T
    CYTOMETRY, 1991, 12 (02): : 155 - 155
  • [28] PROGNOSTIC-SIGNIFICANCE OF DNA CONTENT IN BLADDER-CANCER BASED ON FLOW CYTOMETRIC ANALYSIS OF 249 TRANSITIONAL-CELL CARCINOMAS
    VINDELOV, LL
    CHRISTENSEN, IJ
    ENGELHOLM, SA
    GULDHAMMER, BH
    HOJGAARD, K
    SORENSEN, BL
    WOLF, H
    CYTOMETRY, 1995, 22 (02): : 93 - 102
  • [29] ADN CONTENT MEASURED BY FLOW-CYTOMETRIC IN PARAFFIN EMBEDDED BLADDER-CANCER - CLINICAL-EVALUATION
    BITTARD, H
    LAMY, B
    BILLEREY, C
    KHENIFAR, E
    JOURNAL D UROLOGIE, 1990, 96 (06) : 311 - 313
  • [30] RELATION BETWEEN FLOW CYTOMETRIC DNA DISTRIBUTION AND PATHOLOGY IN HUMAN BLADDER-CANCER - A REPORT ON 69 CASES
    FARSUND, T
    HOESTMARK, JG
    LAERUM, OD
    CANCER, 1984, 54 (09) : 1771 - 1777